T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1501
Oshkosh
OSK
$9.41B
| $4.64M | ﹤0.01% |
41,153
-1,266
| -3% | -$138K |
|
1502
Valvoline
VVV
$4.25B
| $4.48M | ﹤0.01% |
120,029
-3,042
| -2% | -$106K |
|
|
COHR
1503
DELISTED
Coherent Inc
COHR
| $4.47M | ﹤0.01% |
16,760
-7,726
| -32% | -$1.99M |
|
1504
Avis
CAR
$4.93B
| $4.43M | ﹤0.01% |
21,364
-6,141
| -22% | -$1.36M |
|
1505
US Foods
USFD
$24B
| $4.37M | ﹤0.01% |
125,554
-9,712
| -7% | -$338K |
|
1506
eHealth
EHTH
$38.8M
| $4.37M | ﹤0.01% |
171,215
-28,125
| -14% | -$934K |
|
|
AJRD
1507
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $4.33M | ﹤0.01% |
92,590
+4,604
| +5% | +$203K |
|
1508
Huntsman Corp
HUN
$1.78B
| $4.33M | ﹤0.01% |
124,018
-3,549
| -3% | -$116K |
|
|
FSTX
1509
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $4.31M | ﹤0.01% |
858,095
+34,713
| +4% | +$209K |
|
1510
ITT
ITT
$19.4B
| $4.3M | ﹤0.01% |
42,120
-1,453
| -3% | -$142K |
|
|
ONTF
1511
DELISTED
ON24
ONTF
| $4.3M | ﹤0.01% |
247,611
-116,666
| -32% | -$2.08M |
|
1512
Teva Pharmaceuticals
TEVA
$42.6B
| $4.28M | ﹤0.01% |
534,682
+25,852
| +5% | +$233K |
|
1513
Tenet Healthcare
THC
$21.5B
| $4.21M | ﹤0.01% |
51,477
-1,826
| -3% | -$133K |
|
1514
STAG Industrial
STAG
$7.12B
| $4.2M | ﹤0.01% |
87,649
-1,859
| -2% | -$81K |
|
1515
Upstart Holdings
UPST
$3.01B
| $4.18M | ﹤0.01% |
27,637
-124,930
| -82% | -$31.2M |
|
1516
Unilever
UL
$135B
| $4.18M | ﹤0.01% |
69,039
+1,771
| +3% | +$105K |
|
|
DADA
1517
DELISTED
Dada Nexus
DADA
| $4.17M | ﹤0.01% |
316,769
-874,190
| -73% | -$16.9M |
|
1518
GameStop
GME
$8.33B
| $4.16M | ﹤0.01% |
112,236
+4,408
| +4% | +$200K |
|
1519
Patria Investments
PAX
$1.88B
| $4.11M | ﹤0.01% |
253,956
-68,850
| -21% | -$1.18M |
|
1520
Madrigal Pharmaceuticals
MDGL
$12.4B
| $4.11M | ﹤0.01% |
48,453
-9,347
| -16% | -$768K |
|
1521
Aecom
ACM
$8.19B
| $4.02M | ﹤0.01% |
51,958
-3,522
| -6% | -$247K |
|
|
SYNH
1522
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $4.01M | ﹤0.01% |
39,065
-1,686
| -4% | -$162K |
|
1523
UGI
UGI
$7.53B
| $4M | ﹤0.01% |
87,134
-5,490
| -6% | -$244K |
|
|
MPT
1524
Medical Properties Trust
MPT
$2.51B
| $3.94M | ﹤0.01% |
166,689
-16,333
| -9% | -$350K |
|
1525
News Corp Class B
NWS
$17.8B
| $3.89M | ﹤0.01% |
172,706
-7,621
| -4% | -$175K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.